Updates in the Treatment of HR+/HER2- Breast Cancer

William J. Gradishar, MD, provides insights on the evolving treatment landscape of breast cancer management, highlighting updates to NCCN guidelines, the growing role of CDK4/6 inhibitors, and anticipated research findings at ASCO 2024.

EP. 1: Diagnosis and Risk Stratification for Early-Stage HR+/HER2- Breast Cancer

December 24th 2024

Panelists discuss how the NCCN guidelines for risk stratification in HR+/HER2- early-stage breast cancer inform clinical decision-making, with an emphasis on biomarker testing, the use of tools like RSClin N+, and the evolving role of CDK4/6 inhibitors and adjuvant therapies. They also address challenges in risk assessment and the integration of newer treatment strategies, such as CDK4/6 inhibitors and PARP inhibitors in the early-stage setting.

EP. 2: CDK4/6 Inhibitors for HR+/HER2- Early Breast Cancer

January 2nd 2025

Panelists discuss how adjuvant therapy in HR+/HER2- early-stage breast cancer is influenced by key risk factors, with a focus on recent studies involving CDK4/6 inhibitors like abemaciclib, ribociclib, and palbociclib, and how these treatments are shaping the adjuvant treatment strategy based on efficacy data from trials such as MonarchE, NATALEE, and PALLAS.

EP. 3: Current Practices for Targeted Therapies and Molecular Testing for HR+/HER2- Metastatic Breast Cancer

January 14th 2025

Panelists discuss how the latest NCCN guidelines for targeted therapies and biomarker testing in advanced/metastatic breast cancer highlight the importance of biomarker-driven approaches, with particular emphasis on the need for next-generation sequencing testing in the first-line setting, the implications of HER2-low classification, and how the recent FDA approval of a PI3K inhibitor may impact testing practices and treatment strategies.

EP. 4: Exploring 1L and 2L CDK4/6 Inhibitors + Endocrine Therapies

January 21st 2025

Panelists discuss how first- and second-line treatment options for HR+ advanced/metastatic breast cancer, particularly the use of CDK4/6 inhibitors (CDK4/6i) in combination with endocrine therapy, are influenced by clinical factors such as bone metastasis, visceral crisis, and molecular phenotype, while also reviewing the latest clinical trial data, real-world outcomes, and comparative efficacy of ribociclib, abemaciclib, and palbociclib.

EP. 5: Clinical Perspectives: Use of CDK4/6i After CDK4/6i

January 28th 2025

Panelists discuss potential treatment options for patients following progression on CDK4/6 inhibitors (i) in HR+/HER2– metastatic breast cancer.

EP. 6: The Current Treatment Landscape of Oral SERDs in Metastatic Breast Cancer

January 28th 2025

Panelists discuss their overall perceptions of oral selective estrogen receptor degraders (SERDs) and their impact on the treatment landscape and share their experiences with elacestrant in clinical practice.

EP. 7: Clinical Findings of Elacestrant, an Oral SERD for ER+/HER2– Metastatic Breast Cancer

February 4th 2025

Panelists discuss the clinical findings of elacestrant, an oral selective estrogen receptor degrader (SERD), for the treatment of ER+/HER2– metastatic breast cancer.

EP. 8: Emerging Data of Additional SERDs in Metastatic Breast Cancer

February 4th 2025

Panelists discuss recent data on other selective estrogen receptor degraders (SERDs) and their implications in the treatment of HR+/HER2– breast cancer.

EP. 9: CDK4/6 Inhibitors Plus Novel Agents for ER+/HER2–Advanced or mBC

February 11th 2025

Panelists discuss perceptions on the efficacy and safety data for proteolysis targeting chimeras (PROTACs) and the selective estrogen receptor modulator (SERM) lasofoxifene in the treatment of HR+/HER2– breast cancer.

EP. 10: Toxicities and Treatment Selection of Endocrine-Based Therapies in HR+/HER2– Breast Cancer

February 11th 2025

Panelists discuss how genotype-directed treatment options compare with fulvestrant, factors influencing the choice of therapy, and strategies for managing adverse events with this class of therapies.

EP. 11: Genotype-Directed Therapies for HR+/HER2– Advanced Breast Cancer

February 18th 2025

Panelists discuss genotype-directed treatment options for advanced HR+/HER2– disease, including PI3K/AKT/mTOR inhibitors and antibody-drug conjugates (ADCs), their use based on recent data, impressions of these regimens, and how the recent first-line approval of inavolisib in combination with palbociclib and fulvestrant for PI3K-mutated HR+/HER2– metastatic breast cancer may change the treatment paradigm.

EP. 12: Exploring Data of PI3K/AKT/mTOR Inhibitors in HER2– mBC

February 18th 2025

Panelists discuss the use of alpelisib in light of the inavolisib approval and the impact of capivasertib (CAPItello-291 trial) on the treatment landscape and sequencing options for HR+/HER2– metastatic breast cancer (mBC).

EP. 13: Clinical Developments of Antibody-Drug Conjugates (ADCs) in HR+/HER2– mBC

February 25th 2025

Panelists discuss the latest antibody-drug conjugate developments for HR+/HER2– metastatic breast cancer (mBC), including sacituzumab govitecan and trastuzumab deruxtecan.

EP. 14: ADCs: Recent Data of Dato-DXd from TROPION-Breast01

February 25th 2025

Panelists discuss the results of the datopotamab deruxtecan (Dato-DXd) TROPION-Breast01 trial and its potential uses in clinical practice.

EP. 15: Impact of ADC Toxicities and Clinical Decision-Making for mBC

March 4th 2025

Panelists discuss adverse events associated with antibody-drug conjugates (ADCs) that impact clinical decision-making and share strategies for managing these adverse events.

EP. 16: Continued Advances and Treatment Sequencing for HR+/HER2– Breast Cancer

March 4th 2025

Panelists discuss how to choose among therapeutic options when multiple molecular alterations are detected, identify patient populations better suited to specific therapies, and share their excitement about potential advances in the HR+/HER2– breast cancer space.